肿瘤18F-FDG PET中SUV的可重复性
本文综述了肿瘤18F-FDG PET中SUV可重复性的现有数据,讨论了不同可重复性指标、相对单位、对数变换及不对称可重复性限值等方法学问题。在严格遵循协议采集时,肿瘤SUV的受试者内变异系数约为10%;在疗效评估中,SUV降低超过25%和升高超过33%不太可能源于测量变异。
要点
- 严格遵循协议采集时,肿瘤SUV的受试者内变异系数约为10%。
- 疗效评估中,SUV降低超过25%和升高超过33%不太可能源于测量变异。
- 方案依从性较差的中心可能需要更宽的界限,但SUV总体上是高度可重复的影像生物标志物。
核心结论
- 当严格遵循协议采集时,肿瘤SUV的受试者内变异系数约为10%。
- 在疗效评估中,SUV降低超过25%和升高超过33%不太可能源于测量变异。
- 方案依从性较差的中心可能需要更宽的界限,但总体而言SUV是高度可重复的影像生物标志物,适合在个体患者中监测肿瘤治疗反应。
研究设计与样本
- 本文为综述,汇总分析了多次重复扫描测试-再测试研究的数据,这些研究对同一患者在相同扫描仪上按相同协议在不超过数天内重复扫描。
主要发现
- 严格遵循协议采集时,肿瘤SUV的受试者内变异系数约为10%。
- 在疗效评估中,SUV降低超过25%和升高超过33%不太可能源于测量变异。
- 方案依从性较差的中心可能需要更宽的界限。
关键数值与推荐
- 严格遵循协议采集时,肿瘤SUV的受试者内变异系数约为10%。
- 在疗效评估中,SUV降低超过25%和升高超过33%不太可能源于测量变异。
临床怎么用
- 原文未据此给出推荐。
局限性
- SUV存在多种变异来源。
- 不同报告因采用不同方法和统计指标而使比较复杂化。
- 方案依从性较差的中心可能需要更宽的界限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Quantitative analysis can potentially improve the accuracy and consistency of 18F-FDG PET, particularly for the assessment of tumor response to treatment. Although not without limitations, SUV has emerged as the predominant metric for tumor quantification with 18F-FDG PET. Growing literature suggests that the difference between SUVs measured before and after treatment can be used to predict tumor response at an early stage. SUV is, however, associated with multiple sources of variability, and to best use SUV for response assessment, an understanding of the repeatability of the technique is required. Test-retest studies involve repeated scanning of the same patient on the same scanner using the same protocol no more than a few days apart and provide basic information on the repeatability of the technique. Multiple test-retest studies have been performed to assess SUV repeatability, although a comparison of reports is complicated by the use of different methodologies and statistical metrics. This article reviews the available data, addressing issues such as different repeatability metrics, relative units, log transformation, and asymmetric limits of repeatability. When acquired with careful attention to protocol, tumor SUV has a within-subject coefficient of variation of approximately 10%. In a response assessment setting, SUV reductions of more than 25% and increases of more than 33% are unlikely to be due to measurement variability. Broader margins may be required for sites with less rigorous protocol compliance, but in general, SUV is a highly repeatable imaging biomarker that is ideally suited to monitoring tumor response to treatment in individual patients.
引用
- Lodge MA. Repeatability of SUV in Oncologic 18F-FDG PET. J Nucl Med. 2017. PMID: 28232605. doi:10.2967/jnumed.116.186353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。